New study aims to tailor sickle cell drug dosing for nigerian patients

NCT ID NCT07543289

First seen Apr 21, 2026 · Last updated May 14, 2026 · Updated 7 times

Summary

This study will look at how genetics and body processes affect the way Nigerian patients with sickle cell disease respond to the drug hydroxyurea. Researchers will study 100 patients to create a computer model that can help doctors choose the best dose for each person. The goal is to improve treatment and reduce side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Obafemi Awolowo University Teaching Hospital Complex

    Ile-Ife, Osun State, 220282, Nigeria

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.